These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

298 related articles for article (PubMed ID: 29070978)

  • 1. Modulating Cytotoxic Effector Functions by Fc Engineering to Improve Cancer Therapy.
    Kellner C; Otte A; Cappuzzello E; Klausz K; Peipp M
    Transfus Med Hemother; 2017 Sep; 44(5):327-336. PubMed ID: 29070978
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Boosting ADCC and CDC activity by Fc engineering and evaluation of antibody effector functions.
    Kellner C; Derer S; Valerius T; Peipp M
    Methods; 2014 Jan; 65(1):105-13. PubMed ID: 23851282
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dual Fc optimization to increase the cytotoxic activity of a CD19-targeting antibody.
    Gehlert CL; Rahmati P; Boje AS; Winterberg D; Krohn S; Theocharis T; Cappuzzello E; Lux A; Nimmerjahn F; Ludwig RJ; Lustig M; Rösner T; Valerius T; Schewe DM; Kellner C; Klausz K; Peipp M
    Front Immunol; 2022; 13():957874. PubMed ID: 36119088
    [TBL] [Abstract][Full Text] [Related]  

  • 4. An Fc engineering approach that modulates antibody-dependent cytokine release without altering cell-killing functions.
    Kinder M; Greenplate AR; Strohl WR; Jordan RE; Brezski RJ
    MAbs; 2015; 7(3):494-504. PubMed ID: 25933349
    [TBL] [Abstract][Full Text] [Related]  

  • 5. An Fc Double-Engineered CD20 Antibody with Enhanced Ability to Trigger Complement-Dependent Cytotoxicity and Antibody-Dependent Cell-Mediated Cytotoxicity.
    Wirt T; Rosskopf S; Rösner T; Eichholz KM; Kahrs A; Lutz S; Kretschmer A; Valerius T; Klausz K; Otte A; Gramatzki M; Peipp M; Kellner C
    Transfus Med Hemother; 2017 Sep; 44(5):292-300. PubMed ID: 29070974
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Fc Glyco- and Fc Protein-Engineering: Design of Antibody Variants with Improved ADCC and CDC Activity.
    Kellner C; Derer S; Klausz K; Rosskopf S; Wirt T; Rösner T; Otte A; Cappuzzello E; Peipp M
    Methods Mol Biol; 2018; 1827():381-397. PubMed ID: 30196508
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Enhancing CDC and ADCC of CD19 Antibodies by Combining Fc Protein-Engineering with Fc Glyco-Engineering.
    Roßkopf S; Eichholz KM; Winterberg D; Diemer KJ; Lutz S; Münnich IA; Klausz K; Rösner T; Valerius T; Schewe DM; Humpe A; Gramatzki M; Peipp M; Kellner C
    Antibodies (Basel); 2020 Nov; 9(4):. PubMed ID: 33212776
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Fc engineering: design, expression, and functional characterization of antibody variants with improved effector function.
    Derer S; Kellner C; Berger S; Valerius T; Peipp M
    Methods Mol Biol; 2012; 907():519-36. PubMed ID: 22907372
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Fc engineering of antibodies and antibody derivatives by primary sequence alteration and their functional characterization.
    Derer S; Kellner C; Rösner T; Klausz K; Glorius P; Valerius T; Peipp M
    Methods Mol Biol; 2014; 1131():525-40. PubMed ID: 24515488
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Enhancing Fc-mediated effector functions of monoclonal antibodies: The example of HexaBodies.
    van der Horst HJ; Mutis T
    Immunol Rev; 2024 Nov; 328(1):456-465. PubMed ID: 39275983
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Fc-Engineering for Modulated Effector Functions-Improving Antibodies for Cancer Treatment.
    Liu R; Oldham RJ; Teal E; Beers SA; Cragg MS
    Antibodies (Basel); 2020 Nov; 9(4):. PubMed ID: 33212886
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Advances in Therapeutic Fc Engineering - Modulation of IgG-Associated Effector Functions and Serum Half-life.
    Saxena A; Wu D
    Front Immunol; 2016; 7():580. PubMed ID: 28018347
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Development of a robust reporter-based ADCC assay with frozen, thaw-and-use cells to measure Fc effector function of therapeutic antibodies.
    Cheng ZJ; Garvin D; Paguio A; Moravec R; Engel L; Fan F; Surowy T
    J Immunol Methods; 2014 Dec; 414():69-81. PubMed ID: 25086226
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of amino acid substitutions on the biological activity of anti-CD20 monoclonal antibody produced by transgenic silkworms (Bombyx mori).
    Aoyama M; Tada M; Tatematsu KI; Hashii N; Sezutsu H; Ishii-Watabe A
    Biochem Biophys Res Commun; 2018 Sep; 503(4):2633-2638. PubMed ID: 30119885
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Improving Antibody-Based Cancer Therapeutics Through Glycan Engineering.
    Yu X; Marshall MJE; Cragg MS; Crispin M
    BioDrugs; 2017 Jun; 31(3):151-166. PubMed ID: 28466278
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Enhancement of antibody-dependent cell-mediated cytotoxicity by endowing IgG with FcαRI (CD89) binding.
    Borrok MJ; Luheshi NM; Beyaz N; Davies GC; Legg JW; Wu H; Dall'Acqua WF; Tsui P
    MAbs; 2015; 7(4):743-51. PubMed ID: 25970007
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Fc Engineering Strategies to Advance IgA Antibodies as Therapeutic Agents.
    van Tetering G; Evers M; Chan C; Stip M; Leusen J
    Antibodies (Basel); 2020 Dec; 9(4):. PubMed ID: 33333967
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A novel method for determining antibody-dependent cellular phagocytosis.
    Kamen L; Myneni S; Langsdorf C; Kho E; Ordonia B; Thakurta T; Zheng K; Song A; Chung S
    J Immunol Methods; 2019 May; 468():55-60. PubMed ID: 30880262
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Functional comparison of Fc-engineering strategies to improve anti-HIV-1 antibody effector functions.
    Schriek AI; Falck D; Wuhrer M; Kootstra NA; van Gils MJ; de Taeye SW
    Antiviral Res; 2024 Nov; 231():106015. PubMed ID: 39343065
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Fc-Engineered Antibodies with Enhanced Fc-Effector Function for the Treatment of B-Cell Malignancies.
    van der Horst HJ; Nijhof IS; Mutis T; Chamuleau MED
    Cancers (Basel); 2020 Oct; 12(10):. PubMed ID: 33086644
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.